Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Metalloprotease inhibitors with therapeutic potential discovered at Roche

July 5, 2001

Patient enrollment complete in VALIANT trial of Diovan for long-term survival following MI

July 5, 2001

Xanthine-based adenosine receptor antagonists with particular utility in heart and renal failure

July 4, 2001

Potent chymase inhibitors presented by Wakunaga

July 3, 2001

Myocardin, a novel cardiac regulatory gene with potential for heart muscle regeneration

July 3, 2001

New inhibitors of PDGF receptor autophosphorylation designed at JT

July 2, 2001

Phase III clinical trials of CV Therapeutics' CVT-510 commence

July 2, 2001

Biogen presents new series with particular utility in CHF, renal dysfunction

June 29, 2001

Acylsulfonamides as selective chymase inhibitors

June 29, 2001

FDA advisory committee to discuss NDA for Remodulin in August

June 28, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...